Aeterna Zentaris Inc. AEZS

NAS: AEZS | ISIN: CA0079754028   19:36
1,960 USD (+0,26%)
(+0,26%)   19:36

15 maart 2021 · Aeterna Zentaris Announces Exclusive License Agreement and Research Contract with Julius-Maximilians-University Wuerzburg for Development of a Potential Oral Prophylactic Bacterial Vaccine Against COVID-19 · Persbericht

11 maart 2021 · Aeterna Zentaris Continues to Demonstrate Pipeline Expansion – Announces the Initiation of Its Preclinical Program for the Potential Treatment of Primary Hypoparathyroidism · Persbericht

24 februari 2021 · Aeterna Zentaris to Present at the H.C. Wainwright Global Life Sciences Conference · Persbericht

19 februari 2021 · Aeterna Zentaris Announces Closing of $29.7 Million Bought Deal Offering of Common Shares · Persbericht

17 februari 2021 · Aeterna Zentaris Increases Previously Announced Bought Deal Offering of Common Shares to $29.7 Million · Persbericht

16 februari 2021 · Aeterna Zentaris Announces $10.0 Million Bought Deal Offering of Common Shares · Persbericht

2 februari 2021 · Aeterna Zentaris Announces Evaluation and Potential Development of an Oral Prophylactic Bacterial Vaccine Against COVID-19 Through Exclusive Option Agreement with Julius-Maximilians-University Wuerzburg · Persbericht

28 januari 2021 · Aeterna Zentaris Expands Orphan Drug Development Pipeline with Targeted Immunosuppressive Therapeutics · Persbericht

26 januari 2021 · Aeterna Zentaris Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule · Persbericht

15 januari 2021 · Aeterna Zentaris to Present at NobleCon17 · Persbericht

5 januari 2021 · Aeterna Zentaris to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference · Persbericht

Mijn selecties